Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How to apply for vascepa's patient assistance?How does protein binding influence lipitor's removal via kidneys?Defense strategy against generic in niche market?Diltiazem drug class?Bortezomib market france?
See the DrugPatentWatch profile for lurbinectedin
What combinations are already being tested with lurbinectedin? Clinical trials combine lurbinectedin with doxorubicin for soft tissue sarcomas. [1] The same pair is also tested in ovarian cancer, ovarian, ovarian, ovarian, ovarian, ovarian, ovarian, and ovarian. The pair is tested in ovarian cancer. [2] Lurbinectedin plus irinotecan is under evaluation in neuroendocrine tumors. [3] Lurbinectedin and atezolizumab are tested together for small cell lung cancer. [1] When does patent expire? Patent expires December 2027. [4] Can biosimilars enter before patent expiry? No. When does exclusivity expire? Exclusivity expires May 2025. [4] What side effects are patients asking about? Patients report bone marrow suppression, fatigue, and nausea. [1] Who makes lurbinectedin? Zentiva, and also Pharma Mar. [4] Source: [1] ClinicalTrials.gov Source: [2] ClinicalTrials.gov Source: [3] ClinicalTrials.gov Source: [2] ClinicalTrials.gov Source: [4] DrugPatentWatch.com
Other Questions About Lurbinectedin :